4D pharma has treated the first cancer patients in Part B of the Phase I/II trial of MRx0518 in combination with Keytruda (pembrolizumab). Four additional trial sites are to open in the US through July and August to accelerate patient recruitment. MRx0518 is a single strain (Enterococcus gallinarum) live biotherapeutic product that has shown encouraging first-in-class proof of concept clinical data in an oncology setting. A clinical benefit (2 partial responses and 1 stable disease >6 mont
06 Jul 2020
Phase I/II Part B oncology study begins – interim update later in 2020
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Phase I/II Part B oncology study begins – interim update later in 2020
- Published:
06 Jul 2020 -
Author:
Edward Thomason -
Pages:
3
4D pharma has treated the first cancer patients in Part B of the Phase I/II trial of MRx0518 in combination with Keytruda (pembrolizumab). Four additional trial sites are to open in the US through July and August to accelerate patient recruitment. MRx0518 is a single strain (Enterococcus gallinarum) live biotherapeutic product that has shown encouraging first-in-class proof of concept clinical data in an oncology setting. A clinical benefit (2 partial responses and 1 stable disease >6 mont